Structure Therapeutics Inc. (GPCR)
GPCR trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | GPCR on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2023 |
| SEC CIK | 0001888886 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | Cayman Islands |
Financials
Not reported in SEC XBRL data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-09 |
| Cash and burn | $222.0M cash; operating cash flow -$67.7M a quarter. | Report 2026-09-30 |
| Shares outstanding | 71,590,355 (2026-10-31); 60,677,640 a year earlier; 46,386,438 three years earlier. | Cover page 2026-10-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 3 424B5 takedowns, 3 at the market | Latest 2026-05-07 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, San Mateo, California, United States | PCAOB Form AP 2026-03-10 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$144.8M | -$101.7M | $222.0M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q2 2026 2026-06-30 | Not filed | -$106.2M | -$120.1M | $272.6M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q1 2026 2026-03-31 | Not filed | -$76.0M | $15.2M | $316.2M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q4 2025 2025-12-31 | Not filed | $33.0M | -$64.4M | $799.6M | No debt tags | Needs four quarters | 10-K 2026-02-26 |
| Q3 2025 2025-09-30 | Not filed | -$65.7M | -$51.0M | $102.9M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q2 2025 2025-06-30 | Not filed | -$61.7M | -$54.6M | $147.0M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q1 2025 2025-03-31 | Not filed | -$46.8M | -$52.2M | $152.1M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q4 2024 2024-12-31 | Not filed | -$36.5M | -$36.5M | $169.5M | No debt tags | Needs four quarters | 10-K 2026-02-26 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-05-07 |
| Latest annual report | 10-K | 2026-02-26 |
| Latest quarterly / interim | 10-Q | 2026-11-09 |
| Latest current report FORM 8-K | 8-K | 2026-11-09 |
| Latest proxy | DEF 14A | 2026-04-23 |
Source: SEC EDGAR submissions feed, 275 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -1.7% |
| 1 month | -10.4% |
| 3 months | -63.4% |
| Year to date | -71.2% |
| 1 year | -42.9% |
| From 52-week high | -78.7% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| AVLN | Avalyn Pharma Inc. | $29.76 | -1.72% | $1.3B |
| OCUL | Ocular Therapeutix Inc. | $6.01 | -3.22% | $1.3B |
| INVA | Innoviva Inc. | $18.49 | -2.84% | $1.3B |
| GENB | Generate Biomedicines Inc. | $10.49 | -13.09% | $1.4B |
| NUVB | Nuvation Bio Inc. | $3.84 | -3.76% | $1.4B |
| ANAB | AnaptysBio Inc. | $45.73 | -1.12% | $1.4B |
| TYRA | Tyra Biosciences Inc. | $19.74 | -1.42% | $1.4B |
| MLYS | Mineralys Therapeutics Inc. | $14.53 | -5.22% | $1.3B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier